Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Founded in 2013, HighCape Capital is a growth equity fund based in the United States. The firm specializes in the Life Sciences sector, with a team of experienced executives who have backgrounds in founding, financing, and leading various companies. They focus on helping businesses transition from early stages to successful organizations.
HighCape Capital invests in the Life Sciences sector, targeting Connected Health, Medical Devices/Tools, and Biotechnology. The firm typically engages in pre-seed to Series A and Growth Equity stages, employing a hands-on approach to enhance the commercial and operational strategies of its portfolio companies.
HighCape Capital has backed several notable companies, including Cybrexa Therapeutics, which develops innovative cancer therapies, and Alphina Therapeutics, focused on therapeutic development. Additionally, Modifi Biosciences was acquired by Merck in 2024, marking a significant exit for the firm.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.